General Information of Drug Off-Target (DOT) (ID: OTRWKIYY)

DOT Name Pyrin domain-containing protein 2 (PYDC2)
Synonyms Pyrin-only protein 2; cellular POP2; cPOP2
Gene Name PYDC2
Related Disease
Prostate cancer ( )
Prostate carcinoma ( )
Bacterial infection ( )
UniProt ID
PYDC2_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF02758
Sequence
MASSAELDFNLQALLEQLSQDELSKFKSLIRTISLGKELQTVPQTEVDKANGKQLVEIFT
SHSCSYWAGMAAIQVFEKMNQTHLSGRADEHCVMPPP
Function
May play a role in innate immunity by disrupting the interaction between PYCARD and NLRP3, thereby regulating the NLRP3 inflammasome. May also inhibit NF-kappa-B signaling distally by affecting the nuclear accumulation of RELA.
Tissue Specificity Predominantly expressed in peripheral blood. Weakly expressed in testis.
KEGG Pathway
NOD-like receptor sig.ling pathway (hsa04621 )

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Prostate cancer DISF190Y Strong Biomarker [1]
Prostate carcinoma DISMJPLE Strong Biomarker [1]
Bacterial infection DIS5QJ9S moderate Biomarker [2]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the methylation of Pyrin domain-containing protein 2 (PYDC2). [3]
------------------------------------------------------------------------------------

References

1 Novel biomarkers for prostate cancer including noncoding transcripts.Am J Pathol. 2009 Dec;175(6):2264-76. doi: 10.2353/ajpath.2009.080868. Epub 2009 Nov 5.
2 Pyrin-only protein 2 limits inflammation but improves protection against bacteria.Nat Commun. 2017 Jun 5;8:15564. doi: 10.1038/ncomms15564.
3 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.